We as physicians, especially surgeons, tend to operate on the same principle: When things go bad, especially when revenue goes down, we just work harder and see more patients, with the expectation that it will correct and we can maintain.
With the recent approval of a first-in-class radioactive isotope as a treatment for prostate cancer, urologists have a new weapon in their rapidly growing arsenal of therapies designed to fight this disease.
USO co-founders John Forrest, MD, and Robert Bruce, MD, have known each other since the fourth grade. They both attended medical school at the University of Oklahoma and, after some time away from home, ultimately joined two different, well-established practices in north and south Tulsa.
At a time of controversy regarding the value of PSA screening in the early detection of prostate cancer, the AUA has issued a new clinical guideline on the subject and launched an educational campaign designed to share the information with urologists and their patients.